Valuation : CSL Limited

Market Cap 60.48B 52.04B 48.83B 44.68B 83.39B 5,717B 84.05B 578B 225B 2,922B 227B 222B 9,410B P/E 2027 *
20.7x
P/E 2028 * 18.8x
Enterprise Value 69.36B 59.68B 56B 51.24B 95.63B 6,557B 96.39B 662B 258B 3,351B 260B 255B 10,791B EV / Sales 2027 *
4.4x
EV / Sales 2028 * 4.23x
Free-Float
99.97%
Yield 2027 *
2.37%
Yield 2028 * 2.52%
1 day+0.79%
1 week+0.79%
1 month+43.50%
3 months+92.42%
6 months+19.81%
Current year+6.72%
1 week 25
Extreme 25
25.4
1 month 17.9
Extreme 17.9
25.4
Current year 12.7
Extreme 12.7
43.4
1 year 12.7
Extreme 12.7
43.4
3 years 12.7
Extreme 12.7
47.5
5 years 12.7
Extreme 12.7
51
10 years 12.7
Extreme 12.7
52.5
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Change 5-day change 1-year change 3-year change Capi.($)
+0.79%+0.79% - - 59.71B
-1.00%+4.43%+49.60%+2.50% 85.08B
-1.29%+4.27%+519.00%+36.13% 60.21B
+0.95%+1.77%-15.77%-34.78% 59.71B
-1.60%-7.63%-3.65%+31.05% 51.1B
+0.09%-0.14%+11.61%+165.71% 48.73B
+0.83%+1.36%+58.53%-15.69% 32.9B
-0.64%+0.20%+47.19%+102.28% 26.11B
+0.79%-6.56%-2.56%+192.31% 22.6B
+1.10%-0.90%+67.27%+118.01% 16.42B
Average -0.06%-1.40%+81.25%+66.39% 44.76B
Weighted average by Cap. -0.27%-0.78%+97.08%+45.70%

Financials

2027 *2028 *
Net sales 15.75B 13.55B 12.71B 11.63B 21.71B 1,489B 21.88B 150B 58.57B 761B 59.13B 57.84B 2,450B 16.28B 14.01B 13.15B 12.03B 22.45B 1,539B 22.63B 156B 60.57B 787B 61.15B 59.81B 2,533B
Net income 2.83B 2.44B 2.29B 2.09B 3.91B 268B 3.94B 27.07B 10.54B 137B 10.64B 10.41B 441B 3.16B 2.72B 2.55B 2.34B 4.36B 299B 4.39B 30.2B 11.76B 153B 11.87B 11.62B 492B
Net Debt 8.88B 7.64B 7.17B 6.56B 12.24B 839B 12.34B 84.82B 33.03B 429B 33.35B 32.62B 1,382B 8.43B 7.25B 6.81B 6.23B 11.62B 797B 11.71B 80.51B 31.35B 407B 31.65B 30.96B 1,311B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change
26-09-03 25.40 +0.79%
26-09-02 €25.20 +0.80%
26-09-01 €25.00 -1.57%
26-08-31 €25.40 +1.60%
26-08-28 €25.00 -0.79%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
126.29USD
Average target price
119.56USD
Spread / Average Target
-5.32%

Quarterly revenue - Rate of surprise